stockrow
Friday 6 November 2026
Export CVRX’s income statement to Excel — free account
CVRx, Inc.
CVRX Healthcare Medical Devices
CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024.
- Revenue
- −5.84%
- EPS
- −6.12%
- Free cash flow
- −9.91%
- Total debt
- +18.6%
Quarter to September 2026, against a year earlier
0.87
0.60
−40.82%
Follow CVRX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.79 | 2.23 | 4.22 | 3.27 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.38) | (15.44) | (20.50) | (18.98) | |
P/B ratio |
3.45 | 6.83 | 8.57 | 4.71 | |
Price to Tangible BV |
3.45 | 6.83 | 8.57 | 4.71 | |
EV/Sales |
0.84 | 2.18 | 4.04 | 2.87 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.22) | (3.30) | (6.04) | (4.04) | |
EV/FCF |
(1.21) | (3.25) | (5.95) | (3.98) | |
Quick Ratio |
5.46 | 6.65 | 8.58 | 6.49 | |
Current Ratio |
6.80 | 8.04 | 10.20 | 7.63 | |
Net Debt/EBITDA |
0.01 | 0.47 | 1.16 | 2.39 | |
Debt/Assets |
66.95% | 63.47% | 58.65% | 47.25% | |
Debt/Equity |
4.24 | 2.94 | 2.01 | 1.26 | |
Asset Turnover |
0.61 | 0.58 | 0.52 | 0.48 | |
Operating CF/Net income |
0.77 | 0.63 | 0.93 | 0.82 | |
Capex/Depreciation |
(0.34) | (0.38) | (0.42) | (0.28) | |
Interest Coverage |
(8.12) | (8.25) | (7.84) | (7.89) | |
Research and Development Expense of Revenue |
19.19% | 19.93% | 20.88% | 18.72% | |
Selling, General and Administrative Expense of Revenue |
161.86% | 150.38% | 148.68% | 137.35% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
20.76% | 23.34% | 19.74% | 17.43% | |
Graham Net Nets |
0.24 | 0.13 | 0.10 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(114.86%) | (38.52%) | (21.35%) | (28.87%) | |
Free Cash Flow Yield |
(88.18%) | (30.12%) | (16.11%) | (22.00%) | |
Revenue per Share |
0.51 | 0.59 | 0.56 | 0.61 | |
Operating CF per Share |
(0.40) | (0.33) | (0.46) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.40) | (0.34) | (0.47) | (0.38) | |
Cash per Share |
2.16 | 2.44 | 2.74 | 2.90 | |
Shareholders Equity per Share |
0.51 | 0.75 | 1.10 | 1.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.51 | 0.75 | 1.10 | 1.51 | |
Free Cash Flow |
(10.99) | (8.94) | (12.29) | (9.83) | |
Working Capital |
72.51 | 78.36 | 87.26 | 88.33 | |
Capital Expenditures |
(0.10) | (0.11) | (0.12) | (0.07) | |
Net Current Asset Value |
11.23 | 17.16 | 26.13 | 36.18 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.90 | 8.28 | 9.06 | 9.97 | |
Average Payables |
3.89 | 3.45 | 2.87 | 3.21 | |
Average Inventory |
12.51 | 12.37 | 12.04 | 12.16 | |
Average Assets |
99.47 | 105.92 | 114.66 | 119.10 | |
Average Common Equity |
30.94 | 38.94 | 49.23 | 55.19 |
Columns are period end dates · fundamentals updated 5 Nov 2026